<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098537</url>
  </required_header>
  <id_info>
    <org_study_id>2016/427</org_study_id>
    <nct_id>NCT03098537</nct_id>
  </id_info>
  <brief_title>Effects of Enteral Nutrition on Stress Ulcer Hemorrage. Multicenter Randomized Controlled Trial</brief_title>
  <official_title>Effects of Enteral Nutrition on Stress Ulcer Hemorrage. Multicenter Randomized Controlled</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TC Erciyes University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TC Erciyes University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Enteral nutrition can provides prophylaxis against stress ulcer bleeding in critically ill
      patients and there may be no need to use acid suppressing drugs for stress ulcer bleeding
      prophylaxis in these patients. Half of the patients on enteral nutrition will not receive any
      acid suppressing drugs while other half receives it. They will be followed for
      gastrointestinal bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mucosal erosions can occur on luminal surface of stomach in approximately 75-100% patients
      during the first 24 hours of intensive care unit admission. These erosions often cause
      bleeding with penetrating superficial capillaries. Clinically significant bleeding
      (Significant decrease in blood pressure or decrease in hemoglobin level of more than 2 g /
      dL) appears to be less than 5% in ICU patients.

      Enteral nutrition (EN) has protective effects against stress ulcer bleeding by neutralizing
      the acidic pH in the stomach lumen, providing a structural and functional integrity of the
      mucosal surface and trophic effect on the GI mucosa. These effects have been shown in some
      studies. The above-mentioned studies are inadequate for clinicians to make suggestions for
      relation between enteral nutrition and stress ulcer hemorrhage.

      The risk factors for stress ulcer hemorrhage are mechanical ventilation, coagulopathy and
      burns.

      Proton pump inhibitors (PPI) and histamine receptor blockers (H2RB) are the main drugs used
      for stress ulcer bleeding prophylaxis.

      Studies have shown that 90% of patients admitted to intensive care units receive prophylaxis
      for stress ulcer bleeding.

      Drugs (H2RB, PPI) used for prophylaxis against stress ulcer bleeding have some undesirable
      harmful effects in critical illnesses. These drugs, which suppress gastric acid secretion,
      can cause hospital-associated pneumonia and Clostridium difficile enterocolitis.

      The studies, for clinical proposals are generally performed in the 1980s and early 1990s.
      Oral intake was stopped in most of the critically ill patients and early enteral nutrition
      was not widely used at the time of these major studies performed. Patients who are receiving
      EN have been shown to develop less stress ulcer bleeding in some studies. In a limited number
      of animal studies, enteral feeding has been shown to protect stress-related mucosal damage in
      the gastric mucosa.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GI bleeding</measure>
    <time_frame>Subjects will be followed from date of randomization until discharge from the ICU or cessation of enteral nutrition up to four weeks</time_frame>
    <description>Overt GI bleeding (presence of coffee ground emesis hematemesis, melena or hematochezia.
Significant GI bleeding, defined by 3-point decrease in hematocrit within 24 hours accompanied by overt GI bleeding or by an unexplained 6-point decrease in hematocrit during any 48 hour period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Enteral Nutrition</condition>
  <condition>Gastro Intestinal Bleeding</condition>
  <condition>Stress Ulcer Prophylaxis</condition>
  <condition>Proton Pump Inhibitor</condition>
  <arm_group>
    <arm_group_label>Enteral nutrion only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Enteral nutrion + proton pump inhibitor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enteral nutrition + proton pump inhibitor</intervention_name>
    <description>Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive enteral nutrition and proton pump inhibitor</description>
    <arm_group_label>Enteral nutrion + proton pump inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>enteral nutrition only</intervention_name>
    <description>Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive only enteral nutrition.</description>
    <arm_group_label>Enteral nutrion only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Admission to ICU

          -  Expected to stay in ICU &gt;24 hours

          -  No contraindications to EN within the first 24 hours after admission to the intensive
             care unit

        Exclusion Criteria:

          -  Evidence of active GI bleeding during current hospitalization prior to study entry

          -  Coagulopathy (PLT&lt;50.000, INR&gt;1.5, aPTT&gt;2xcontrol)

          -  Patients receiving acid suppressing drugs prior to admission

          -  Pregnancy or lactation

          -  History/documented gastric ulcer

          -  Burn&gt;30% body surface area

          -  Head injury or increased intracranial pressure

          -  Partial or complete gastrectomy

          -  Shock

          -  Multi-system trauma

          -  Exposure to gastric irritant drugs

          -  Patients not giving informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kurat Gundogan, MD</last_name>
    <phone>+90 352 207 6666</phone>
    <phone_ext>21919</phone_ext>
    <email>kgundogan@erciyes.edu.tr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Murat Sungur, MD</last_name>
    <phone>+90 352 207 6666</phone>
    <phone_ext>21912</phone_ext>
    <email>msungur@erciyes.edu.tr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erciyes University Medical School</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kudret Dogru, MD</last_name>
      <phone>+90 352 207 6666</phone>
      <phone_ext>20000</phone_ext>
      <email>kdogru@erciyes.edu.tr</email>
    </contact>
    <contact_backup>
      <last_name>Emine Alp, MD</last_name>
      <phone>+90 352 207 6666</phone>
      <phone_ext>20000</phone_ext>
      <email>ealp@erciyes.edu.tr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, Winton TL, Rutledge F, Todd TJ, Roy P, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med. 1994 Feb 10;330(6):377-81.</citation>
    <PMID>8284001</PMID>
  </reference>
  <reference>
    <citation>Raff T, Germann G, Hartmann B. The value of early enteral nutrition in the prophylaxis of stress ulceration in the severely burned patient. Burns. 1997 Jun;23(4):313-8.</citation>
    <PMID>9248640</PMID>
  </reference>
  <reference>
    <citation>Ephgrave KS, Kleiman-Wexler RL, Adair CG. Enteral nutrients prevent stress ulceration and increase intragastric volume. Crit Care Med. 1990 Jun;18(6):621-4.</citation>
    <PMID>2111755</PMID>
  </reference>
  <reference>
    <citation>Shorr LD, Sirinek KR, Page CP, Levine BA. The role of glucose in preventing stress gastric mucosal injury. J Surg Res. 1984 Apr;36(4):384-8.</citation>
    <PMID>6546772</PMID>
  </reference>
  <reference>
    <citation>Pingleton SK, Hadzima SK. Enteral alimentation and gastrointestinal bleeding in mechanically ventilated patients. Crit Care Med. 1983 Jan;11(1):13-6.</citation>
    <PMID>6401236</PMID>
  </reference>
  <reference>
    <citation>Cook DJ, Reeve BK, Guyatt GH, Heyland DK, Griffith LE, Buckingham L, Tryba M. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA. 1996 Jan 24-31;275(4):308-14.</citation>
    <PMID>8544272</PMID>
  </reference>
  <reference>
    <citation>Daley RJ, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: current trends in critical care. Crit Care Med. 2004 Oct;32(10):2008-13.</citation>
    <PMID>15483408</PMID>
  </reference>
  <reference>
    <citation>Pisegna JR. Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition. Crit Care Med. 2002 Jun;30(6 Suppl):S356-61. Review.</citation>
    <PMID>12072661</PMID>
  </reference>
  <reference>
    <citation>Lin PC, Chang CH, Hsu PI, Tseng PL, Huang YB. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. Crit Care Med. 2010 Apr;38(4):1197-205. doi: 10.1097/CCM.0b013e3181d69ccf.</citation>
    <PMID>20173630</PMID>
  </reference>
  <reference>
    <citation>Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009 May 27;301(20):2120-8. doi: 10.1001/jama.2009.722.</citation>
    <PMID>19470989</PMID>
  </reference>
  <reference>
    <citation>Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003 Jul;54(3):243-5.</citation>
    <PMID>12855243</PMID>
  </reference>
  <reference>
    <citation>Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004 Jul 6;171(1):33-8.</citation>
    <PMID>15238493</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2017</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>TC Erciyes University</investigator_affiliation>
    <investigator_full_name>Kursat Gundogan</investigator_full_name>
    <investigator_title>Associate Professor of Medicine and Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

